Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 14/20 | 0.69 |
| ▸ | ACHE | P22303 | 7/20 | 0.69 |
| ▸ | CNR2 | P34972 | 6/20 | 0.68 |
| ▸ | CNR1 | P21554 | 7/20 | 0.63 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11672709 | 1.00 | APP (1.00) | APPBCHEACHECNR2CNR1 | |
| Hydrochloric Acid SCHEMBL11732727 | 0.99 | APP (0.98) | APPBCHEACHECNR2CNR1 | |
| Oxalic Acid SCHEMBL11736596 | 0.97 | APP (0.94) | APPBCHEACHECNR2CNR1 | |
| SCHEMBL11672560 | 0.95 | APP (0.91) | APPBCHEACHECNR2CNR1 | |
| SCHEMBL11672546 | 0.93 | APP (0.87) | APPBCHEACHECNR2CNR1 | |
| SCHEMBL11672542 | 0.93 | APP (0.87) | APPBCHEACHECNR2CNR1 | |
| SCHEMBL11730748 | 0.92 | APP (0.85) | APPBCHEACHECNR2CNR1 | |
| SCHEMBL11673509 | 0.92 | APP (0.85) | APPBCHEACHECNR2CNR1 | |
| SCHEMBL11673919 | 0.91 | APP (0.84) | APPBCHEACHECNR2CNR1 | |
| SCHEMBL11672485 | 0.91 | APP (0.84) | APPBCHEACHECNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2719394-B1 | Peptides for treating amyloid-associated diseases | UNIV TEL AVIV FUTURE TECH DEV (IL) | 2015-07-29 | — | — | EP | disclosed |
| US-8993510-B2 | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2015-03-31 | — | — | US | disclosed |
| EP-2719394-A1 | Peptides antibodies directed thereagainst for diagnosing and treating amyloid-associated diseases | Tel Aviv University Future Technology Development L.P. (IL) | 2014-04-16 | — | — | EP | disclosed |
| US-8697634-B2 | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2014-04-15 | — | — | US | disclosed |
| US-20130338076-A1 | PEPTIDES AND METHODS USING SAME FOR DIAGNOSIS AND TREATMENT OF AMYLOID-ASSOCIATED DISEASE | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2013-12-19 | — | — | US | disclosed |
| US-8563273-B2 | Method of screening for compounds that disaggregate amyloid aggregates | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2013-10-22 | — | — | US | disclosed |
| US-8012929-B2 | Peptides directed for diagnosis and treatment of amyloid-associated diseases | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2011-09-06 | — | — | US | disclosed |
| US-7781396-B2 | Peptides directed for diagnosis and treatment of amyloid-associated disease | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2010-08-24 | — | — | US | disclosed |
| US-20100105608-A1 | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2010-04-29 | — | — | US | disclosed |
| US-20100022459-A1 | Peptides directed for diagnosis and treatment of amyloid-associated diseases | Tel Aviv University Future Technology Development L.P (IL) | 2010-01-28 | — | — | US | disclosed |
| US-20070021345-A1 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2007-01-25 | — | — | US | disclosed |
| US-20060234947-A1 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | Tel Aviv University Future Technology Development L.P (IL) | 2006-10-19 | — | — | US | disclosed |
| EP-1534310-A4 | PEPTIDES ANTIBODIES DIRECTED THEREAGAINST AND METHODS USING SAME FOR DIAGNOSING AND TREATING AMYLOID-ASSOCIATED DISEASES | UNIV TEL AVIV FUTURE TECH DEV (IL) | 2006-05-31 | — | — | EP | disclosed |
| EP-1638517-A2 | PEPTIDES ANTIBODIES DIRECTED THEREAGAINST AND METHODS USING SAME FOR DIAGNOSING AND TREATING AMYLOID-ASSOCIATED DISEASES | Tel Aviv University Future Technology Development L.P. (IL) | 2006-03-29 | — | — | EP | disclosed |
| EP-1534310-A2 | PEPTIDES ANTIBODIES DIRECTED THEREAGAINST AND METHODS USING SAME FOR DIAGNOSING AND TREATING AMYLOID-ASSOCIATED DISEASES | Tel Aviv University Future Technology Development L.P. (IL) | 2005-06-01 | — | — | EP | disclosed |
| US-20050020809-A1 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2005-01-27 | — | — | US | disclosed |
| WO-2005000193-A2 | PEPTIDES ANTIBODIES DIRECTED THEREAGAINST AND METHODS USING SAME FOR DIAGNOSING AND TREATING AMYLOID-ASSOCIATED DISEASES | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2005-01-06 | — | — | WO | disclosed |
| US-20040052928-A1 | A peptide containing at least 5 amino acid residues and less than 15 amino acid residues; | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT, L.P. (IR) | 2004-03-18 | — | — | US | disclosed |
| WO-2003063760-A2 | PEPTIDES ANTIBODIES DIRECTED THEREAGAINST AND METHODS USING SAME FOR DIAGNOSING AND TREATING AMYLOID-ASSOCIATED DISEASES | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2003-08-07 | — | — | WO | disclosed |
| US-4001426-A | HAVING CORONARY VASODILATOR ACTIVITY | SMITHKLINE CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234947-A1 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | IAPP, NGLY1, APP | APP 3/4885BCHE 174/4885ACHE 579/4885 |
| US-20100022459-A1 | Peptides directed for diagnosis and treatment of amyloid-associated diseases | APP, IAPP, PEPD | APP 1/4885BCHE 142/4885ACHE 839/4885 |
| US-20130338076-A1 | PEPTIDES AND METHODS USING SAME FOR DIAGNOSIS AND TREATMENT OF AMYLOID-ASSOCIATED DISEASE | APP, IAPP, ENPEP | APP 1/4885BCHE 158/4885ACHE 659/4885 |
| US-20070021345-A1 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | IAPP, NGLY1, APP | APP 3/4885BCHE 174/4885ACHE 579/4885 |
| US-20100105608-A1 | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease | APP, IAPP, ENPEP | APP 1/4885BCHE 158/4885ACHE 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.